ADH (antidiuretic hormone), also called AVP (arginine vasopressin), is a nine-amino-acid peptide hormone synthesized in the paraventricular nucleus and supraoptic nucleus of the Hypothalamus, released from the posterior pituitary, that orchestrates water retention, vasoconstriction, and stress-responsive behaviors. Evolutionarily critical for survival during Dehydration and blood loss, chronic ADH elevation in modern contexts drives hypertension, edema, and metabolic dysfunction. ADH operates through three receptor subtypes (V1a, V1b/V3, V2) with distinct tissue distributions and downstream effects.
Think of ADH as the emergency water conservation officer in a city facing drought. When the reservoirs (blood volume) drop or the water becomes too salty (high osmolality >280 mOsm/kg), the officer (ADH) springs into action with three strategies. First, he radios the water treatment plant (kidneys) to activate the V2 receptors, which insert aquaporin-2 water channels into the collecting duct cells—like opening emergency water reclamation gates that pull water back from the sewage system (urine) into the city supply (bloodstream). Second, he calls the municipal works department (vascular smooth muscle) via V1a receptors to tighten all the water pipes (vasoconstriction), raising pressure throughout the system. Third, he alerts the city council (pituitary) through V1b receptors to activate the broader disaster response (ACTH and cortisol release). This worked brilliantly when droughts were occasional emergencies—hunter-gatherers crossing deserts, losing blood from injury. But in modern life, chronic psychological stress keeps the officer permanently on edge, conserving water even when the reservoirs are full, leading to chronically high blood pressure and waterlogged tissues.
graph TD
A["Osmoreceptors >280 mOsm/kg OR<br/>Volume receptors <10% blood loss"] --> B["Paraventricular Nucleus + Supraoptic Nucleus"]
B --> C[ADH synthesis as pro-hormone]
C --> D[Magnocellular neurons project to posterior pituitary]
D --> E[ADH released into circulation]
E --> F[V2 receptors - kidney collecting duct]
E --> G[V1a receptors - vascular smooth muscle]
E --> H[V1b/V3 receptors - anterior pituitary]
F --> F1["Gs protein activation → cAMP"]
F1 --> F2[PKA activation]
F2 --> F3[Aquaporin-2 insertion into apical membrane]
F3 --> F4[Water reabsorption from urine]
G --> G1["Gq protein activation → PLC"]
G1 --> G2["IP3 + DAG → Ca²⁺ release"]
G2 --> G3[Smooth muscle contraction]
G3 --> G4["Vasoconstriction + BP increase"]
H --> H1[Gq protein activation]
H1 --> H2[ACTH release]
H2 --> H3[Cortisol synthesis]
Synthesis and Release:
Hypothalamic neurons in the paraventricular nucleus (PVN, parvocellular and magnocellular divisions) and supraoptic nucleus (SON, primarily magnocellular) produce ADH from a 164-amino acid preprohormone. The hormone is packaged with neurophysin II and copeptin into secretory granules. Magnocellular axons project to the posterior pituitary, where ADH is stored in nerve terminals.
Release Triggers:
- Osmotic: Osmoreceptors in the organum vasculosum of the lamina terminalis (OVLT) and subfornical organ detect plasma osmolality >280 mOsm/kg (normal 275-295)
- Volumetric: Baroreceptors in carotid sinus and aortic arch detect >10% blood volume decrease
- Stress: CRH and IL-1β directly stimulate ADH release independent of osmolality
- Nausea: Area postrema stimulation triggers massive ADH release (nausea is often ADH-mediated)
Receptor Signaling:
V2 receptors (kidney collecting duct principal cells):
- Gs-coupled → cAMP → PKA
- PKA phosphorylates aquaporin-2 (AQP2) at Ser256
- Phosphorylated AQP2 translocates from intracellular vesicles to apical membrane
- Water flows down osmotic gradient from tubular fluid to medullary interstitium
- Chronic V2 activation increases AQP2 gene expression via CREB phosphorylation
- Effect magnitude: ADH increases urine osmolality from 50 to 1200 mOsm/kg
V1a receptors (vascular smooth muscle, hepatocytes, platelets):
- Gq-coupled → phospholipase C → IP3 + DAG
- IP3 releases Ca²⁺ from sarcoplasmic reticulum
- Ca²⁺-calmodulin activates myosin light chain kinase
- Smooth muscle contraction → systemic vasoconstriction
- Hepatic V1a → glycogenolysis (evolutionary preparation for fight-or-flight)
- Platelet V1a → aggregation (wound-sealing response)
V1b/V3 receptors (anterior pituitary corticotrophs):
- Gq-coupled → synergizes with CRH to amplify ACTH release
- V1b knockout mice show 50% reduction in stress-induced cortisol
- Creates positive feedback: stress → ADH → ACTH → Cortisol → more stress perception
Metabolic Regulation:
ADH is degraded by aminopeptidases (plasma half-life 10-20 minutes). Pregnancy and chronic liver disease reduce degradation, contributing to hyponatremia. Alcohol suppresses ADH release (mechanism of alcohol-induced diuresis), while nicotine and opioids stimulate it.
Evolutionary Context:
ADH was under intense positive selection during human migration out of Africa into arid environments. Hunter-gatherers faced episodic Dehydration (days without water sources), traumatic hemorrhage (hunting injuries), and orthostatic challenges (rapid postural changes). ADH's triple action (water retention + vasoconstriction + stress priming) was lifesaving. The evolutionary mismatch emerges when chronic psychological stress, inflammatory signals (IL-1β, IL-6), and sedentary lifestyle activate ADH tonically, creating pathological states.
Chronic Stress and Hypertension:
In chronic stress, sustained CRH elevation drives persistent ADH release even when plasma osmolality is normal (280 mOsm/kg). This creates:
- Chronic V1a-mediated vasoconstriction → essential hypertension (ADH contributes to 30-40% of stress-induced BP elevation)
- Chronic V2 activation → subtle plasma volume expansion → cardiac preload increase
- Synergy with Cortisol (which upregulates V1a receptors) amplifies hypertension
- Clinical threshold: Plasma ADH >5 pg/mL in euvolemic, non-stressed state suggests chronic activation
SIADH (Syndrome of Inappropriate ADH):
Occurs in:
- Pulmonary infections (pneumonia stimulates vagal afferents → ADH release)
- Cancer (especially small-cell lung cancer producing ectopic ADH)
- SSRIs (serotonin enhances ADH release from PVN)
- Post-surgical pain and nausea
- Results in hyponatremia (<135 mEq/L), concentrated urine (>100 mOsm/kg) despite low plasma osmolality
- Severe cases (<120 mEq/L) cause cerebral edema, seizures
Metabolic Dysfunction:
Chronic ADH elevation contributes to insulin resistance through:
- V1a-mediated hepatic glycogenolysis → postprandial hyperglycemia
- Cortisol co-elevation (via V1b) → visceral adiposity
- Volume expansion → renal sodium retention → aldosterone suppression paradox
Depression and ADH:
The PVN co-releases 5-HT and ADH (both from same neurons). In Depression, this system is dysregulated:
- Elevated ADH contributes to psychomotor retardation (via central V1a)
- Morning ADH peaks correlate with morning depression severity
- SSRIs initially worsen SIADH risk before long-term receptor downregulation
cPNI Intervention Strategy:
- Hydration assessment: Urine specific gravity <1.020, Urine density assessment, adequate water intake (30-40 mL/kg/day)
- Stress axis regulation: Mindfulness, breathing exercises, vagus nerve stimulation to reduce CRH-driven ADH
- Address inflammation: IL-1β antagonism (via Omega-3 fatty acids, Curcumin, Specialized pro-resolving mediators (SPMs)) reduces inflammatory ADH triggers
- Sleep optimization: ADH shows circadian variation (peak 02:00-04:00); poor sleep flattens rhythm
- Avoid triggers: Minimize SSRIs if hyponatremia risk, address nausea aggressively, caution with NSAIDs (which impair renal ADH response)
Exam-Relevant Clinical Scenario:
A 45-year-old woman with chronic stress, Depression, and newly started on sertraline (SSRI) presents with fatigue, confusion, and serum sodium 128 mEq/L. Urine osmolality is 450 mOsm/kg despite low plasma osmolality. This is SSRI-induced SIADH mediated by serotonergic enhancement of PVN ADH release. Management includes SSRI dose reduction, water restriction (800-1000 mL/day), and addressing underlying chronic stress with non-pharmacological interventions.
- Synthesized in paraventricular nucleus and supraoptic nucleus as 164-amino acid preprohormone
- Normal plasma ADH: 1-5 pg/mL; >5 pg/mL suggests inappropriate activation
- Release triggered at plasma osmolality >280 mOsm/kg (0.8-1% increase sufficient)
- Half-life: 10-20 minutes (rapid degradation by aminopeptidases)
- V2 receptors (kidney): water reabsorption via aquaporin-2 insertion
- V1a receptors (vasculature): Gq → IP3/DAG → Ca²⁺ → vasoconstriction
- V1b/V3 receptors (pituitary): synergize with CRH to amplify ACTH 2-3 fold
- Can increase urine osmolality from 50 to 1200 mOsm/kg (24-fold concentration)
- Alcohol suppresses ADH (mechanism of diuresis); nicotine and opioids stimulate it
- Co-released with Oxytocin from PVN during social bonding and stress
- SIADH diagnostic criteria: plasma osmolality <275, urine osmolality >100, serum sodium <135
- Chronic elevation contributes to 30-40% of stress-induced hypertension
- Evolutionarily adaptive for Dehydration survival; maladaptive in chronic stress
- Peak circadian release 02:00-04:00 (coordinates with Cortisol nadir)
- paraventricular nucleus — primary synthesis site for ADH in magnocellular and parvocellular neurons
- Oxytocin — co-produced in PVN magnocellular neurons, co-released during stress and bonding
- 5-HT — PVN serotonergic neurons co-release ADH; serotonin enhances ADH secretion
- dorsal raphe nucleus — receives PVN serotonin/ADH projections; reciprocal regulation of stress response
- CRH — directly stimulates ADH release from PVN; V1b receptors amplify CRH-induced ACTH
- Cortisol — upregulates V1a receptors, creating positive feedback for vasoconstriction
- ACTH — V1b/V3 receptors on corticotrophs synergize with CRH to drive ACTH release
- Hypothalamus — origin of ADH synthesis and osmotic/volumetric sensing
- posterior pituitary — storage and release site for ADH from magnocellular axon terminals
- OVLT — osmoreceptor site that detects >280 mOsm/kg and triggers ADH release
- Dehydration — evolutionary primary trigger; increases plasma osmolality and ADH secretion
- chronic stress — pathological ADH driver via CRH, independent of osmolality
- IL-1β — inflammatory cytokine that directly stimulates PVN ADH release
- IL-6 — contributes to stress-induced ADH elevation and SIADH in sepsis
- SSRIs — serotonin enhancement increases ADH release risk of hyponatremia in 10-15% of patients
- Depression — PVN ADH dysregulation contributes to psychomotor symptoms and HPA axis dysfunction
- insulin resistance — chronic ADH drives hepatic glucose output via V1a receptors
- hypertension — chronic V1a-mediated vasoconstriction plus volume expansion from V2 activation
- edema — excess V2-driven water retention in heart failure, cirrhosis, SIADH
- Allostatic load — chronic ADH elevation is a measurable component of cumulative physiological burden
- Autonomic nervous system — baroreceptor input regulates ADH via brainstem integration
- Intrauterine programming — maternal stress-induced ADH crosses placenta, programs fetal HPA axis
- Evolutionary mismatch — adaptive for episodic dehydration/hemorrhage; maladaptive in chronic psychological stress
- Alcohol — suppresses ADH release via hypothalamic inhibition (diuretic effect)
- Exercise — acute exercise transiently increases ADH for blood pressure maintenance during exertion
- Omega-3 fatty acids — EPA/DHA reduce IL-1β-driven ADH release, mitigating inflammatory SIADH